In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua ...

For minor vision loss, simple adjustments like using brighter lights, wearing anti-glare sunglasses and using magnifiers can help. Changing the settings on your phone and computer to increase contrast ...

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Age-related macular degeneration (AMD) once meant a slow, irreversible loss of vision, and many people still believe that's ...

A wireless retinal implant called PRIMA is changing that reality by helping blind patients read and recognize faces again.

The new pathway has improved communication between primary and secondary care, and reduced waiting times for treatment ...